NDT Advance Access originally published online on May 5, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nephrol Dial Transplant (2004) 19: 1886-1889
Nephrol Dial Transplant Vol. 19 No. 7 © ERA-EDTA 2004; all rights reserved
Brief Report
Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients
1 Department of Medicine, Kidney Center, Tokyo Women's Medical University and 2 Minami Senju Hospital, Tokyo, Japan
Correspondence and offprint requests to: Kosaku Nitta, MD, Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. Email: nitta{at}kc.twmu.ac.jp
Background. Osteoprotegerin (OPG) is a glycoprotein that inhibits osteoclast differentiation and activity. OPG-deficient mice develop severe osteoporosis and medial arterial calcification. The expression of OPG is detected in early atherosclerotic lesions in non-uraemic patients. We examined whether serum OPG is associated with aortic calcification in haemodialysis patients.
Methods. Serum OPG was measured in 102 patients who were undergoing haemodialysis. The aortic calcification index (ACI) was assessed by computed tomography scans.
Results. Serum OPG level, measured by enzyme-linked immunosorbent assay, was significantly greater in patients with higher ACI than in those with lower ACI. There was a direct relationship between ACI and serum OPG levels and a positive association between OPG and ACI (r = 0.483, P<0.0001). Multiple regression analyses indicated that serum OPG levels were independently associated with the severity of aortic calcification (P<0.0001).
Conclusions. These findings show that serum OPG levels are associated with the extent of vascular calcification, suggesting that OPG may be involved in the development of vascular calcification in haemodialysis patients.
Keywords: arteriosclerosis; calcinosis; glycoprotein; renal dialysis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Morena, A.-M. Dupuy, I. Jaussent, H. Vernhet, G. Gahide, K. Klouche, A.-S. Bargnoux, C. Delcourt, B. Canaud, and J.-P. Cristol A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3389 - 3397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Lewiecki Denosumab in postmenopausal osteoporosis: what the clinician needs to know Therapeutic Advances in Musculoskeletal Diseases, October 1, 2009; 1(1): 13 - 26. [Abstract] [PDF]
|
|
|
|
|
|
M. K. Sigrist, A. Levin, L. Er, and C. W. McIntyre Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3157 - 3162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Panizo, A. Cardus, M. Encinas, E. Parisi, P. Valcheva, S. Lopez-Ongil, B. Coll, E. Fernandez, and J. M. Valdivielso RANKL Increases Vascular Smooth Muscle Cell Calcification Through a RANK-BMP4-Dependent Pathway Circ. Res., May 8, 2009; 104(9): 1041 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y.-M. Wang VASCULAR AND OTHER TISSUE CALCIFICATION IN PERITONEAL DIALYSIS PATIENTS Perit. Dial. Int., February 1, 2009; 29(Supplement_2): S9 - S14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J BOWDEN, S R I AITKEN, I B WILKINSON, and A K DIXON Interobserver variability in the measurement of abdominal aortic calcification using unenhanced CT Br. J. Radiol., January 1, 2009; 82(973): 69 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Morony, Y. Tintut, Z. Zhang, R. C. Cattley, G. Van, D. Dwyer, M. Stolina, P. J. Kostenuik, and L. L. Demer Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr( / ) Mice Circulation, January 22, 2008; 117(3): 411 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stompor AN OVERVIEW OF THE PATHOPHYSIOLOGY OF VASCULAR CALCIFICATION IN CHRONIC KIDNEY DISEASE Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S215 - S222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stompor, M. Krzanowski, B. Kusnierz-Cabala, M. Dubiel, M. Stompor, T. Grodzicki, and W. Sulowicz Pulse wave velocity and proteins regulating vascular calcification and bone mineralization in patients treated with peritoneal dialysis Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3605 - 3606. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Clancy, L. Oliver, R. Jayalath, P. Buttner, and J. Golledge Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2574 - 2576. [Full Text] [PDF]
|
|
|
|
|
|
R. Westenfeld, M. Ketteler, and V. M. Brandenburg Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2075 - 2077. [Full Text] [PDF]
|
|
|
|
|
|
C. W. McIntyre Is it practical to screen dialysis patients for vascular calcification? Nephrol. Dial. Transplant., February 1, 2006; 21(2): 251 - 254. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Morena, N. Terrier, I. Jaussent, H. Leray-Moragues, L. Chalabi, J.-P. Rivory, F. Maurice, C. Delcourt, J.-P. Cristol, B. Canaud, et al. Plasma Osteoprotegerin Is Associated with Mortality in Hemodialysis Patients J. Am. Soc. Nephrol., January 1, 2006; 17(1): 262 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rogers and R. Eastell Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Y. Qunibi Reducing the Burden of Cardiovascular Calcification in Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., November 1, 2005; 16(11_suppl_2): S95 - S102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rattazzi, B. J. Bennett, F. Bea, E. A. Kirk, J. L. Ricks, M. Speer, S. M. Schwartz, C. M. Giachelli, and M. E. Rosenfeld Calcification of Advanced Atherosclerotic Lesions in the Innominate Arteries of ApoE-Deficient Mice: Potential Role of Chondrocyte-Like Cells Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1420 - 1425. [Abstract] [Full Text] [PDF]
|
|